Fasting's cardiometabolic payoff is real, measurable and modest

Intermittent fasting is widely promoted for weight loss and for managing metabolic problems, but a diet's real value for long-term health rests on whether it moves the markers that predict heart disease and diabetes. Those cardiometabolic risk factors include weight, waist circumference, blood pressure, blood glucose, insulin and blood lipids. Individual trials of fasting have been small and inconsistent, so this review set out to pool them and ask whether the pattern across all randomised evidence genuinely favours fasting over a control diet.

The authors systematically searched PubMed, Embase and the Cochrane Library up to October 2020 for randomised controlled trials comparing an intermittent fasting intervention against a control group diet. Fourteen effect sizes were pooled and expressed as weighted mean differences. The outcomes covered body weight, waist circumference, fat mass, BMI, systolic and diastolic blood pressure, fasting glucose, fasting insulin, insulin resistance, and a full lipid panel including total cholesterol, triglycerides, LDL and HDL.

Fasting groups lost 1.78 kg more body weight than controls, along with 1.26 kg more fat mass, 1.19 cm more off the waist and a 0.58 kg/m2 larger drop in BMI. Systolic blood pressure fell by 2.14 mmHg and diastolic by 1.38 mmHg. Fasting insulin, insulin resistance, total cholesterol and triglycerides all improved by small but statistically significant margins. Notably, LDL cholesterol, HDL cholesterol and glycosylated haemoglobin showed no effect at all.

This review supports fasting as a genuine, if modest, tool for improving the cluster of risk factors that make up cardiometabolic health. The effect sizes are small in absolute terms, which fits the broader pattern in diet research where most approaches deliver kilograms rather than transformations. The null results for LDL, HDL and long-term blood sugar temper the enthusiasm, and the authors flag that longer, better designed trials are needed before definitive conclusions can be drawn.

If you are considering intermittent fasting for heart and metabolic health rather than just the scale, this evidence suggests it moves most of the right needles, but gently. The lack of movement in LDL cholesterol and long-term blood sugar is worth knowing, because those are markers many people specifically hope a diet will fix. This is a reason to view fasting as one contributor to cardiometabolic health rather than a complete solution on its own.